COULD THE
ACTUALLY BE
HEMATOLOGIC
BPDCN?
CANCER
YOU JUST
What the CD 123 diagnostic marker
can tell you
DIAGNOSED …
CD123
CD4
CD56
Knowing can be as simple as CD 123
CD 123
is a rapidly emerging therapeutic target in
hematologic cancer. 1
A signature triad of diagnostic markers, including
CD 123, may help identify the aggressive and
deadly hematologic cancer BPDCN—an often
underrecognized and misdiagnosed disease. 1-4 *
BPDCN may present as other
hematologic cancers, including 1,3-5 :
• AML • NHL
• MDS • CMML
• ALL
CONSIDER CD 123 IN EVERY HEMATOLOGIC DIAGNOSTIC PANEL. 1
Visit BPDCNinfo.com
BPDCN = blastic plasmacytoid dendritic cell neoplasm; AML = acute myeloid leukemia; NHL = non-Hodgkin’s lymphoma; ALL = acute lymphoblastic leukemia;
MDS = myelodysplastic syndrome; CMML = chronic myelomonocytic leukemia.
*BPDCN diagnosis can include other markers, such as TCL1 and CD 303 (BDCA2). 6
References: 1. Pagano L, Valentini CG, Grammatico S, Pulsoni A. Br J Haematol. 2016;174(2):188-202. 2. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S,
Vermi W. Mod Pathol. 2016;29(2):98-111. 3. Riaz W, Zhang L, Horna P, Sokol L. Cancer Control. 2014;21(4):279-289. 4. Pemmaraju N. Curr Hematol Malig Rep.
2017;12(6):510-512. 5. Laribi K, Denizon N, Besançon A, et al. Biol Blood Marrow Transplant. 2016;22(8):1357-1367. 6. Reichard KK. Surg Pathol Clin.
2013;6(4):743-765.
Copyright 2018 - Stemline Therapeutics, Inc.
All rights reserved.
3/2018
2018002